The Content
Agency for Healthcare Research and Quality (AHRQ) - Advancing Excellence in Health Care US Department of Health and Human Services - Improving the health, safety, and well-being of America
AHRQ 2011 Publications Online Store - ahrqpubs.ahrq.gov
Online Store Home Page FAQs
       
        
Cart
Cart
   Profile
Profile
  
Login
   Register
Register
      
 
  
Back to Top
  

  Effective Health Care

Alternative OrderingPhone: 1-800-358-9295; Outside of the United States: 703-437-2078; TTY/TDD: 1-888-586-6340
Mail: AHRQ Publications Clearinghouse, P.O. Box 8547, Silver Spring, MD 20907-8547
 
  "ACE Inhibitors" and "ARBs" to Protect Your Heart? A Guide for Patients Being Treated for Stable Coronary Heart Disease AHRQ 10-EHC002-A
Agency for Healthcare Research and Quality, May 2010, 12 pp. (English version). Provides information on the efficacy and safety of using ACE inhibitors, ARBs, or their combination vs. standard medical therapy.  
 
Product Cost:  $0.50   EACH
 
  A Progress Report on AHRQ's Effective Health Care Program: Commentary AHRQ 08-R006
C. Clancy, J. Slutsky, Health Services Research, 42(5):October 2007, xi-xix. Provides an update on the progress of AHRQ's Effective Health Care Program, describes the interest that the program has garnered recently, and discusses some observations about the program since its inception in 2003.  
 
Product Cost:  $0.00   EACH
 
  ACEIs or ARBs for Adults with Hypertension: Clinician's Guide AHRQ 08-EHC003-3
Agency for Healthcare Research and Quality, October 2007, 2 pp. Summarizes evidence comparing the effectiveness and safety of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists when used by adults with essential hypertension.  
 
Product Cost:  $0.15   EACH
 
  AHRQ's Effective Health Care Program: Why Comparative Effectiveness Matters AHRQ 09-R028
J. Slutsky, C. Clancy, American Journal of Medical Quality 24(1):January/February 2009, 67-70. Defines comparative effectiveness research and discusses the use of these research findings in making comparisons of treatment alternatives.  
 
Product Cost:  $0.00   EACH
 
  Adding ACEIs and/or ARBs to Standard Therapy for Stable Ischemic Heart Disease: Benefits and Harms: Clinician Guide AHRQ 10-EHC002-3
Agency for Healthcare Research and Quality, Month 2010, 2 pp. Discusses whether standard medical therapy in patients with stable ischemic heart disease should be augmented with an angiotensin-converting enzyme inhibitor or an angiotensin II receptor blocker.  
 
Product Cost:  $0.15   EACH
 
  Adding the Patient Perspective to Comparative Effectiveness Research AHRQ 11-R022
A. Wu, C. Snyder, Cl Clancy, et al., Health Affairs, October 2010; 29(10):1863-1871. Describes how questionnaires can be used systematically to capture patients' experiences with care directly from the patients.  
 
Product Cost:  $0.00   EACH
 
  Advancing Methods for Comparative Effectiveness Research AHRQ 10-R075
S. Smith, Medical Care, June 2010; 48(6 suppl 1):S1-S2. Editorial discusses AHRQ's role in advancing new scientific approaches for conducting studies on comparative effectiveness and safety and introduces a journal supplement that presents the proceedings of a 2009 AHRQ-supported symposium focused on this topic.  
 
Product Cost:  $0.00   EACH
 
  CER: Tools--Not Rules, and Its Effects Can Be Transformational AHRQ 11-R010
C. Clancy, Medscape, August 2010; e-pub. Commentary discusses comparative effectiveness research and its role in helping clinicians deliver safe, effective health care.  
 
Product Cost:  $0.00   EACH
 
  Charting a Path From Comparative Effectiveness Funding To Improved Patient-Centered Health Care AHRQ 10-R048
P. Conway, C. Clancy, Journal of the American Medical Association, March 2010; 303(10):985-986. Editorial comments on a study that presents publication criteria for studies that assess the comparative effectiveness of medications and discusses next steps for disseminating and translating comparative effectiveness research into practice.  
 
Product Cost:  $0.00   EACH
 
  Choosing Antidepressants for Adults, Clinician's Guide AHRQ 07-EHC007-3
Agency for Healthcare Research and Quality, August 2007 4 pp. Summarizes clinical research comparing the effectiveness and safety of commonly used antidepressants for adults with major depression.  
 
Product Cost:  $0.15   EACH
 
  Choosing Antidepressants for Adults: A Guide for Adults with Depression AHRQ 07-EHC007-2A
Agency for Healthcare Research and Quality, August 2007, 9 pp. Booklet provides information to help adult patients work with their doctors to choose medicines for depression. Describes the various medications used to treat adults with depression, possible side effects, and cost of the drugs.  
 
Product Cost:  $0.50   EACH
 
  Choosing Medications for Rheumatoid Arthritis: Clinician's Guide AHRQ 08-EHC004-3
Agency for Healthcare Research and Quality, April 2008, 4 pp. Summarizes evidence comparing the effectiveness and safety of disease-modifying antirheumatic drugs and corticosteroids used for rheumatoid arthritis.  
 
Product Cost:  $0.15   EACH
 
  Choosing Non-Opioid Analgesics for Osteoarthritis, Clinician's Guide AHRQ 06(07)-EHC009-3
Agency for Healthcare Research and Quality, January 2007, 4 pp. Summarizes clinical evidence on the effectiveness and safety of non-opioid analgesics for osteoarthritis based on a systematic review of 351 research publications.  
 
Product Cost:  $0.15   EACH
 
  Choosing Pain Medicine for Osteoarthritis: A Guide for Consumers. Effective Health Care AHRQ 06(07)-EHC009-2A
Agency for Healthcare Research and Quality, January 2007, 9 pp. Booklet describes the different kinds of pain relievers that are available to treat osteoarthritis and presents information about the trade-offs between pain relief, potential side-effects, and medication cost.  
 
Product Cost:  $0.50   EACH
 
  Comparative Effectiveness Research Priorities at Federal Agencies: The View from the Department of Veterans Affairs, National Institute on Aging, and Agency for Healthcare Research and Quality AHRQ 10-R078
T. O'Leary, J. Slutsky, M. Bernard, Journal of the American Geriatrics Society, June 2010; 58(6):1187-1192. Briefly describes the research mission of AHRQ, NIA, and VA, discusses various definitions of comparative effectiveness research, and sets forth approaches in which the three agencies support comparative effectiveness research involving the aging population, as well as opportunities for future research in this area.  
 
Product Cost:  $0.00   EACH
 
  Comparative Effectiveness Research and Genomic Medicine: An Evolving Partnership for 21st Century Medicine AHRQ 10-R033
J. Khoury, E. Rich, G. Randhawa, et al., Genetics in Medicine, October 2009; 11(10):707-711. Commentary argues the position that comparative effectiveness and genomic medicine not only can and should coexist, but they also will increasingly benefit from each other to enhance knowledge-based medical practice.  
 
Product Cost:  $0.00   EACH
 
  Comparative Effectiveness Research: Promising Area of Study for Pharmacists AHRQ 10-R065
C. Clancy, Journal of the American Pharmaceutical Association, March-April 2010; 50(2):131-133. Defines comparative effectiveness research and discusses AHRQ's research in this area, including several studies that are directly relevant to pharmacists.  
 
Product Cost:  $0.00   EACH
 
  Comparative Effectiveness Reviews Comparative Effectiveness and Safety of Analgesics for Osteoarthritis. AHRQ 06-EHC009-1
Agency for Healthcare Research and Quality, Executive Summary No. 4, September 2006, 12 pp. Summarizes the available evidence comparing the benefits and harms of analgesics in the treatment of osteoarthritis.  
 
Product Cost:  $0.00   EACH
 
  Comparative Effectiveness and Safety of Oral Diabetes Medications for Adults with Type 2 Diabetes. Executive Summary AHRQ 07-EHC010-1
Agency for Healthcare Research and Quality. Executive Summary No. 8, July 2007, 2007, 16 pp. Summarizes the available evidence on the safety and effectiveness of oral diabetes medications used by adults with type 2 diabetes.  
 
Product Cost:  $0.00   EACH
 
  Comparative Effectiveness and Safety of Radiotherapy Treatments for Head and Neck Cancer: Clinician Guide AHRQ 10(11)-EHC014-3
Agency for Healthcare Research and Quality, September 2010, 2 pp. Examines the comparative effectiveness and safety of external beam radiation therapies for head and neck cancer.  
 
Product Cost:  $0.15   EACH
 
  Comparative Effectiveness of Angiotensin Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Added to Standard Medical Therapy for Treating Stable Ischemic Heart Disease AHRQ 10-EHC002-1
Agency for Healthcare Research and Quality, Executive Summary No. 18, October 2009, 24 pp. Summarizes the available evidence comparing the efficacy and safety of using ACE inhibitors, ARBs, or their combination vs. standard medical therapy in a population with stable ischemic heart disease, or an ischemic heart disease risk equivalent, and preserved left ventricular function.  
 
Product Cost:  $0.00   EACH
 
  Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin II Receptor Antagonists (ARBs) for Treating Essential Hypertension AHRQ 08-EHC003-1
Agency for Healthcare Research and Quality, Comparative Effectiveness Review Executive Summary No. 10, November 2007, 5 pp. Summarizes the evidence on the comparative long-term benefits and harms of ACEIs vs. ARBs, focusing on their use for treating essential hypertension in adults.  
 
Product Cost:  $0.00   EACH
 
  Comparative Effectiveness of Core-Needle and Open Surgical Biopsy for the Diagnosis of Breast Lesions AHRQ 10-EHC007-1
Agency for Healthcare Research and Quality, Executive Summary No. 19, December 2009, 19 pp. Evaluates the accuracy of different methods of performing breast biopsy and explores what factor(s) may impact the accuracy and possible harms of different methods of performing breast biopsy.  
 
Product Cost:  $0.00   EACH
 
  Comparative Effectiveness of Drug Therapy for Rheumatoid Arthritis and Psoriatic Arthritis in Adults AHRQ 08-EHC004-1
Agency for Healthcare Research and Quality, Comparative Effectiveness Review, Executive Summary No. 11, November 2007, 11 pp. Summarizes the evidence on the comparative efficacy, effectiveness, and harms of corticosteroids and synthetic and biologic disease-modifying antirheumatic drugs in the treatment of patients with rheumatoid arthritis or psoriatic arthritis.  
 
Product Cost:  $0.00   EACH
 
  Comparative Effectiveness of Epoetin and Darbeopetin for Managing Anemia in Patients Undergoing Cancer Treatment. AHRQ 06-EHC008-1
Agency for Healthcare Research and Quality, Executive Summary No. 3, May 2006. Focuses on use of epoetin and darbepoetin to manage anemia in patients undergoing cancer treatment with chemotherapy and/or radiation.  
 
Product Cost:  $0.00   EACH

Previous 1 - 25 Next 25
  
Welcome
Guest
Login

Register

View Shopping Cart
No items

View Saved Carts

View Shopping Lists


AHRQ - Advancing Excellence in Health Care